Next Cure, Inc. NXTC
We take great care to ensure that the data presented and summarized in this overview for NextCure, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NXTC
View all-
Sofinnova Investments, Inc. Menlo Park, CA2.67MShares$1.36 Million0.17% of portfolio
-
Affinity Asset Advisors, LLC New York, NY2.3MShares$1.17 Million0.32% of portfolio
-
Citigroup Inc1.39MShares$708,4100.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.14MShares$582,0120.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA987KShares$503,5350.0% of portfolio
-
Black Rock Inc. New York, NY761KShares$388,2010.0% of portfolio
-
Tang Capital Management LLC San Diego, CA700KShares$357,0000.04% of portfolio
-
Cable Car Capital LLC San Francisco, CA616KShares$314,0970.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny519KShares$264,8430.0% of portfolio
-
Acadian Asset Management LLC Boston, MA488KShares$249,1040.0% of portfolio
Latest Institutional Activity in NXTC
Top Purchases
Top Sells
About NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Insider Transactions at NXTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
May 13
2019
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
350,000
+11.43%
|
$5,250,000
$15.0 P/Share
|
|
May 13
2019
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
2,361,013
+32.95%
|
-
|
|
May 13
2019
|
Canaan X L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
50,000
+2.17%
|
$750,000
$15.0 P/Share
|
|
May 13
2019
|
Canaan X L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,204,442
+31.87%
|
-
|